<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Elbatrawy AA</submitter><funding>Boston University</funding><funding>Edward Lowe Foundation</funding><funding>NIA NIH HHS</funding><funding>Michigan State University</funding><funding>NINDS NIH HHS</funding><funding>Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation</funding><funding>NIH</funding><funding>Alzheimer&amp;apos;s Association</funding><funding>Lowe Foundation</funding><pagination>117990</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11645236</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>116</volume><pubmed_abstract>Tau and α-synuclein (α-syn) are prone-to-aggregate proteins that can be responsible for pathological lesions found in the brains of Alzheimer's disease (AD), Lewy body dementia (LBD), and Parkinson's disease (PD) patients. The early-stage oligomers and protofibrils of tau are believed to be strongly linked to human cognitive impairment while the toxic α-syn oligomers are associated with behavioral motor deficits. Therefore, concurrent targeting of both proteinaceous aggregates and oligomers are very challenging. Herein, rhodanine-based compounds were designed and synthesized to target the fibrils and oligomers of tau and α-syn proteins. In particular, the indole-containing rhodanines 5l and 5r displayed significantly high anti-aggregation activity towards α-syn fibrils by reducing of the t</pubmed_abstract><journal>Bioorganic &amp; medicinal chemistry</journal><pubmed_title>Exploring the rhodanine universe: Design and synthesis of fluorescent rhodanine-based derivatives as anti-fibrillar and anti-oligomer agents against α-synuclein and 2N4R tau.</pubmed_title><pmcid>PMC11645236</pmcid><funding_grant_id>R21 NS121826</funding_grant_id><funding_grant_id>K08 AG071985</funding_grant_id><funding_grant_id>NS121826</funding_grant_id><funding_grant_id>R01 NS099328</funding_grant_id><funding_grant_id>NS099328</funding_grant_id><funding_grant_id>AARFD-17-529742</funding_grant_id><funding_grant_id>1N4R</funding_grant_id><funding_grant_id>AG071985</funding_grant_id><pubmed_authors>Elbatrawy AA</pubmed_authors><pubmed_authors>Alnakhala H</pubmed_authors><pubmed_authors>Fortin JS</pubmed_authors><pubmed_authors>Perry G</pubmed_authors><pubmed_authors>Dettmer U</pubmed_authors><pubmed_authors>Zhu X</pubmed_authors><pubmed_authors>Tripathi A</pubmed_authors><pubmed_authors>Plascencia-Villa G</pubmed_authors><pubmed_authors>Ademoye TA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Exploring the rhodanine universe: Design and synthesis of fluorescent rhodanine-based derivatives as anti-fibrillar and anti-oligomer agents against α-synuclein and 2N4R tau.</name><description>Tau and α-synuclein (α-syn) are prone-to-aggregate proteins that can be responsible for pathological lesions found in the brains of Alzheimer's disease (AD), Lewy body dementia (LBD), and Parkinson's disease (PD) patients. The early-stage oligomers and protofibrils of tau are believed to be strongly linked to human cognitive impairment while the toxic α-syn oligomers are associated with behavioral motor deficits. Therefore, concurrent targeting of both proteinaceous aggregates and oligomers are very challenging. Herein, rhodanine-based compounds were designed and synthesized to target the fibrils and oligomers of tau and α-syn proteins. In particular, the indole-containing rhodanines 5l and 5r displayed significantly high anti-aggregation activity towards α-syn fibrils by reducing of the t</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Dec</publication><modification>2025-04-04T09:13:01.038Z</modification><creation>2025-04-04T09:13:01.038Z</creation></dates><accession>S-EPMC11645236</accession><cross_references><pubmed>39550891</pubmed><doi>10.1016/j.bmc.2024.117990</doi></cross_references></HashMap>